Study identifier:D5660C00001
ClinicalTrials.gov identifier:NCT01839604
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients with Advanced/Metastatic Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Phase 1
No
AZD9150
All
58
Interventional
18 Years - 150 Years
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 May 2016 by AstraZeneca
AstraZeneca
Isis Pharmaceuticals, Inc.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD9150 There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B). | Drug: AZD9150 Intravenous infusion over 3 hours. Other Name: ISIS 481464 |